OHSU Knight Cancer Institute
@ohsuknight.bsky.social
A leader in cancer research, the OHSU Knight Cancer Institute provides individually-tailored, compassionate care for patients, from diagnosis through survivorship.
Pinned
Phil and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s Knight Cancer Institute to transform the future of cancer care and set a new standard globally.
Thank you to Phil and Penny Knight for their incredible generosity.
#GiveCancerHell
Thank you to Phil and Penny Knight for their incredible generosity.
#GiveCancerHell
“Some might ask why a #BreastCancer drug would work in #AML. But biology can be shared across different cancers. This is a great example of why keeping an open mind matters and following the data where it leads.”
- Dr. Jeffrey Tyner on her #OHSUResearch
- Dr. Jeffrey Tyner on her #OHSUResearch
January 7, 2026 at 7:07 PM
“Some might ask why a #BreastCancer drug would work in #AML. But biology can be shared across different cancers. This is a great example of why keeping an open mind matters and following the data where it leads.”
- Dr. Jeffrey Tyner on her #OHSUResearch
- Dr. Jeffrey Tyner on her #OHSUResearch
We have awarded grants to eight organizations across Oregon to address cancer needs, expanding access to prevention, screening and support services.
Since 2014, the Community Partnership Program has invested over $6.6 million in 246 projects.
Since 2014, the Community Partnership Program has invested over $6.6 million in 246 projects.
January 6, 2026 at 6:43 PM
We have awarded grants to eight organizations across Oregon to address cancer needs, expanding access to prevention, screening and support services.
Since 2014, the Community Partnership Program has invested over $6.6 million in 246 projects.
Since 2014, the Community Partnership Program has invested over $6.6 million in 246 projects.
OHSU researchers have discovered a promising new drug combination that may help people with #AML overcome resistance to one of the most common frontline therapies.
“Of the 25 drug combinations tested, venetoclax plus palbociclib was the most effective.”
- Dr. Melissa Stewart, lead author
“Of the 25 drug combinations tested, venetoclax plus palbociclib was the most effective.”
- Dr. Melissa Stewart, lead author
January 5, 2026 at 11:30 PM
OHSU researchers have discovered a promising new drug combination that may help people with #AML overcome resistance to one of the most common frontline therapies.
“Of the 25 drug combinations tested, venetoclax plus palbociclib was the most effective.”
- Dr. Melissa Stewart, lead author
“Of the 25 drug combinations tested, venetoclax plus palbociclib was the most effective.”
- Dr. Melissa Stewart, lead author
"Having a blood test that detects a signal for a cancer in somebody with no symptoms and then seeing it confirmed on imaging? It’s a game-changer. It’s completely revolutionary."
- Dr. Nima Nabavizadeh on the PATHFINDER 2 study, the largest multi-cancer early detection trial in North America
- Dr. Nima Nabavizadeh on the PATHFINDER 2 study, the largest multi-cancer early detection trial in North America
January 5, 2026 at 5:16 PM
"Having a blood test that detects a signal for a cancer in somebody with no symptoms and then seeing it confirmed on imaging? It’s a game-changer. It’s completely revolutionary."
- Dr. Nima Nabavizadeh on the PATHFINDER 2 study, the largest multi-cancer early detection trial in North America
- Dr. Nima Nabavizadeh on the PATHFINDER 2 study, the largest multi-cancer early detection trial in North America
"Having a blood test that detects a signal for a #cancer in somebody with no symptoms and then seeing it confirmed on imaging? It’s a game-changer. It’s completely revolutionary." - Dr. Nima Nabavizadeh. https://bit.ly/4pfg6Va
Blood test finds seven times more cancers than standard screenings
OHSU radiation oncologist presents promising study findings, launches a third, Medicare-backed study.
news.ohsu.edu
December 29, 2025 at 9:49 PM
"Having a blood test that detects a signal for a #cancer in somebody with no symptoms and then seeing it confirmed on imaging? It’s a game-changer. It’s completely revolutionary." - Dr. Nima Nabavizadeh. https://bit.ly/4pfg6Va
Looking ahead, the #OHSUResearch team plans to continue exploring various uses and potential impacts of ferumoxytol in combination with other contrast agents and imaging techniques, such as PET/MRI and hypoxia imaging.
Learn more: https://bit.ly/4rW8YPY
Learn more: https://bit.ly/4rW8YPY
OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging
OHSU lab started exploring new use of the drug 30 years ago; now, it may improve techniques to measure, monitor aggressive brain tumors.
bit.ly
December 26, 2025 at 4:20 PM
Looking ahead, the #OHSUResearch team plans to continue exploring various uses and potential impacts of ferumoxytol in combination with other contrast agents and imaging techniques, such as PET/MRI and hypoxia imaging.
Learn more: https://bit.ly/4rW8YPY
Learn more: https://bit.ly/4rW8YPY
Reposted by OHSU Knight Cancer Institute
It’s that day again…
Filler up
In the hospital 4 my
Chemo infusion
4 Vasculitis
Just wanna say how
Awesomely awesome
The nurses are
@ohsuknight.bsky.social
love Love LOVE them
(Esp Tika 💖)
Send me mojo so I can
Do this today
And then pull off Xmas
Tomorrow
AND my son’s bday
Xmas day…
#Mm
Filler up
In the hospital 4 my
Chemo infusion
4 Vasculitis
Just wanna say how
Awesomely awesome
The nurses are
@ohsuknight.bsky.social
love Love LOVE them
(Esp Tika 💖)
Send me mojo so I can
Do this today
And then pull off Xmas
Tomorrow
AND my son’s bday
Xmas day…
#Mm
December 23, 2025 at 8:02 PM
It’s that day again…
Filler up
In the hospital 4 my
Chemo infusion
4 Vasculitis
Just wanna say how
Awesomely awesome
The nurses are
@ohsuknight.bsky.social
love Love LOVE them
(Esp Tika 💖)
Send me mojo so I can
Do this today
And then pull off Xmas
Tomorrow
AND my son’s bday
Xmas day…
#Mm
Filler up
In the hospital 4 my
Chemo infusion
4 Vasculitis
Just wanna say how
Awesomely awesome
The nurses are
@ohsuknight.bsky.social
love Love LOVE them
(Esp Tika 💖)
Send me mojo so I can
Do this today
And then pull off Xmas
Tomorrow
AND my son’s bday
Xmas day…
#Mm
Did luck help generate a cancer breakthrough?
On their latest podcast, the American Council on Science & Health focuses on recent #OHSUResearch identifying a promising molecule for the treatment of triple-negative #BreastCancer.
Listen: https://bit.ly/4ja7iOW
On their latest podcast, the American Council on Science & Health focuses on recent #OHSUResearch identifying a promising molecule for the treatment of triple-negative #BreastCancer.
Listen: https://bit.ly/4ja7iOW
Podcast: Dumb Luck Might Have Generated a Cancer Breakthrough
In the high-stakes arena of cancer drug development, SU212 was engineered as a safer twist on podophyllotoxin—a toxic killer designed to halt rogue cell division. Yet in a twist worthy of scientific s...
bit.ly
December 24, 2025 at 4:46 PM
Did luck help generate a cancer breakthrough?
On their latest podcast, the American Council on Science & Health focuses on recent #OHSUResearch identifying a promising molecule for the treatment of triple-negative #BreastCancer.
Listen: https://bit.ly/4ja7iOW
On their latest podcast, the American Council on Science & Health focuses on recent #OHSUResearch identifying a promising molecule for the treatment of triple-negative #BreastCancer.
Listen: https://bit.ly/4ja7iOW
Reposted by OHSU Knight Cancer Institute
This work represents a major milestone in understanding how peroxisomal transporters function at the molecular level. Gupta lab members- @nkhandelwal.bsky.social and , @devinseka.bsky.social made critical contributions that pushed this project forward.
December 23, 2025 at 3:18 AM
This work represents a major milestone in understanding how peroxisomal transporters function at the molecular level. Gupta lab members- @nkhandelwal.bsky.social and , @devinseka.bsky.social made critical contributions that pushed this project forward.
Reposted by OHSU Knight Cancer Institute
Exciting holiday present for the Gupta lab! 🎉 🎊
Our paper "Molecular mechanism of substrate transport by human peroxisomal ABCD3" is now published in @pnas.org !! 🎉 🎊 lnkd.in/gPaFdEMn.
@ohsunews.bsky.social #OHSU #mguptalab #NIHfunded
www.mguptalab.com
Our paper "Molecular mechanism of substrate transport by human peroxisomal ABCD3" is now published in @pnas.org !! 🎉 🎊 lnkd.in/gPaFdEMn.
@ohsunews.bsky.social #OHSU #mguptalab #NIHfunded
www.mguptalab.com
LinkedIn
This link will take you to a page that’s not on LinkedIn
lnkd.in
December 23, 2025 at 3:18 AM
Exciting holiday present for the Gupta lab! 🎉 🎊
Our paper "Molecular mechanism of substrate transport by human peroxisomal ABCD3" is now published in @pnas.org !! 🎉 🎊 lnkd.in/gPaFdEMn.
@ohsunews.bsky.social #OHSU #mguptalab #NIHfunded
www.mguptalab.com
Our paper "Molecular mechanism of substrate transport by human peroxisomal ABCD3" is now published in @pnas.org !! 🎉 🎊 lnkd.in/gPaFdEMn.
@ohsunews.bsky.social #OHSU #mguptalab #NIHfunded
www.mguptalab.com
This season of giving, help us at OHSU do what we do best — provide exceptional health care for those in need in our community — by making a gift today.
Your generosity will make the new year bright and ignite hope for patients, health care professionals, students, and more: https://bit.ly/4pU5qMO
Your generosity will make the new year bright and ignite hope for patients, health care professionals, students, and more: https://bit.ly/4pU5qMO
December 22, 2025 at 9:15 PM
This season of giving, help us at OHSU do what we do best — provide exceptional health care for those in need in our community — by making a gift today.
Your generosity will make the new year bright and ignite hope for patients, health care professionals, students, and more: https://bit.ly/4pU5qMO
Your generosity will make the new year bright and ignite hope for patients, health care professionals, students, and more: https://bit.ly/4pU5qMO
Sometimes it's better to be lucky than good 🔬
On their latest podcast, the American Council on Science & Health focuses on recent #OHSUResearch identifying a promising molecule for the treatment of triple-negative #BreastCancer.
Listen: https://bit.ly/4ja7iOW
On their latest podcast, the American Council on Science & Health focuses on recent #OHSUResearch identifying a promising molecule for the treatment of triple-negative #BreastCancer.
Listen: https://bit.ly/4ja7iOW
Podcast: Dumb Luck Might Have Generated a Cancer Breakthrough
In the high-stakes arena of cancer drug development, SU212 was engineered as a safer twist on podophyllotoxin—a toxic killer designed to halt rogue cell division. Yet in a twist worthy of scientific s...
bit.ly
December 22, 2025 at 8:55 PM
Sometimes it's better to be lucky than good 🔬
On their latest podcast, the American Council on Science & Health focuses on recent #OHSUResearch identifying a promising molecule for the treatment of triple-negative #BreastCancer.
Listen: https://bit.ly/4ja7iOW
On their latest podcast, the American Council on Science & Health focuses on recent #OHSUResearch identifying a promising molecule for the treatment of triple-negative #BreastCancer.
Listen: https://bit.ly/4ja7iOW
“The FDA approval of ferumoxytol for imaging is an exciting advancement for the field of neuro-oncology because it offers a new approach to imaging assessment, which may lead to improving the quality of life for patients.”
- Dr. Ramon Barajas on #OHSUResearch: https://bit.ly/4rW8YPY
- Dr. Ramon Barajas on #OHSUResearch: https://bit.ly/4rW8YPY
OHSU research drives FDA approval for novel use of anemia drug in brain cancer imaging
OHSU lab started exploring new use of the drug 30 years ago; now, it may improve techniques to measure, monitor aggressive brain tumors.
bit.ly
December 19, 2025 at 4:47 PM
“The FDA approval of ferumoxytol for imaging is an exciting advancement for the field of neuro-oncology because it offers a new approach to imaging assessment, which may lead to improving the quality of life for patients.”
- Dr. Ramon Barajas on #OHSUResearch: https://bit.ly/4rW8YPY
- Dr. Ramon Barajas on #OHSUResearch: https://bit.ly/4rW8YPY
📣 Save the Date | Oregon Drug Discovery Symposium (ODDS) 2026
The symposium takes place April 8–9, 2026, and will feature scientific talks, discussions, and a poster session, providing a forum for knowledge exchange across disciplines.
Register: https://bit.ly/4qbMRU0
The symposium takes place April 8–9, 2026, and will feature scientific talks, discussions, and a poster session, providing a forum for knowledge exchange across disciplines.
Register: https://bit.ly/4qbMRU0
December 19, 2025 at 4:13 PM
📣 Save the Date | Oregon Drug Discovery Symposium (ODDS) 2026
The symposium takes place April 8–9, 2026, and will feature scientific talks, discussions, and a poster session, providing a forum for knowledge exchange across disciplines.
Register: https://bit.ly/4qbMRU0
The symposium takes place April 8–9, 2026, and will feature scientific talks, discussions, and a poster session, providing a forum for knowledge exchange across disciplines.
Register: https://bit.ly/4qbMRU0
Reposted by OHSU Knight Cancer Institute
Cancer research is a cornerstone of Oregon’s bioscience sector, generating $11.5B in economic activity in 2023. The PBJ spoke w/ @ohsuknight.bsky.social researchers about what’s needed to sustain innovation & how partnerships can shape a healthier future.
#CancerResearch #Bioscience #CommunityImpact
#CancerResearch #Bioscience #CommunityImpact
Table of Experts: Partnerships accelerate progress in cancer research, treatment - Portland Business Journal
Recently, The Kuni Foundation sponsored a conversation with the Portland Business Journal about the challenges and opportunities impacting our state’s cancer research ecosystem, and what is needed to ...
www.bizjournals.com
December 18, 2025 at 6:25 PM
Cancer research is a cornerstone of Oregon’s bioscience sector, generating $11.5B in economic activity in 2023. The PBJ spoke w/ @ohsuknight.bsky.social researchers about what’s needed to sustain innovation & how partnerships can shape a healthier future.
#CancerResearch #Bioscience #CommunityImpact
#CancerResearch #Bioscience #CommunityImpact
“I’m not going to stop running. I’m going to trust my body and try to put myself in the best position to fight this.”
Matt Hazard was determined to race in the Boston Marathon even after learning he was diagnosed with #ColorectalCancer: https://bit.ly/44rKQKZ
Matt Hazard was determined to race in the Boston Marathon even after learning he was diagnosed with #ColorectalCancer: https://bit.ly/44rKQKZ
December 18, 2025 at 4:55 PM
“I’m not going to stop running. I’m going to trust my body and try to put myself in the best position to fight this.”
Matt Hazard was determined to race in the Boston Marathon even after learning he was diagnosed with #ColorectalCancer: https://bit.ly/44rKQKZ
Matt Hazard was determined to race in the Boston Marathon even after learning he was diagnosed with #ColorectalCancer: https://bit.ly/44rKQKZ
Reposted by OHSU Knight Cancer Institute
The term "recovery friendly workplace" refers to businesses that have taken steps to prevent and respond to substance misuse. Join #OccHealthSci on Jan 15 for a full-day of valuable insights into what it takes to make your workplace recovery friendly. https://loom.ly/AuPakLY
December 16, 2025 at 8:02 PM
The term "recovery friendly workplace" refers to businesses that have taken steps to prevent and respond to substance misuse. Join #OccHealthSci on Jan 15 for a full-day of valuable insights into what it takes to make your workplace recovery friendly. https://loom.ly/AuPakLY
“We’re now identifying many survivors six years out, which is remarkable for a population that had very few options and minimal expectations for any meaningful survival.”
- Dr. Richard Maziarz on one of the earliest CAR-T studies
#OHSUResearch: https://bit.ly/4oL3BjJ
- Dr. Richard Maziarz on one of the earliest CAR-T studies
#OHSUResearch: https://bit.ly/4oL3BjJ
December 15, 2025 at 9:19 PM
“We’re now identifying many survivors six years out, which is remarkable for a population that had very few options and minimal expectations for any meaningful survival.”
- Dr. Richard Maziarz on one of the earliest CAR-T studies
#OHSUResearch: https://bit.ly/4oL3BjJ
- Dr. Richard Maziarz on one of the earliest CAR-T studies
#OHSUResearch: https://bit.ly/4oL3BjJ
For Matt Hazard, there may not have been a better decision than listening to his cousin, who urged him to get a colonoscopy.
Matt received multidisciplinary care for his #ColorectalCancer diagnosis at OHSU, all while training for the Boston Marathon: https://bit.ly/44rKQKZ
Matt received multidisciplinary care for his #ColorectalCancer diagnosis at OHSU, all while training for the Boston Marathon: https://bit.ly/44rKQKZ
December 12, 2025 at 9:10 PM
For Matt Hazard, there may not have been a better decision than listening to his cousin, who urged him to get a colonoscopy.
Matt received multidisciplinary care for his #ColorectalCancer diagnosis at OHSU, all while training for the Boston Marathon: https://bit.ly/44rKQKZ
Matt received multidisciplinary care for his #ColorectalCancer diagnosis at OHSU, all while training for the Boston Marathon: https://bit.ly/44rKQKZ
Mark your calendars for April 10, 2026! 🗓️
Join us for the annual OHSU Knight Cancer Symposium in Portland, Oregon.
Stay updated on the latest advancements in cancer care, research, and programs.
Don't miss this opportunity to learn from experts!
Register today: https://bit.ly/4rH8ygm
Join us for the annual OHSU Knight Cancer Symposium in Portland, Oregon.
Stay updated on the latest advancements in cancer care, research, and programs.
Don't miss this opportunity to learn from experts!
Register today: https://bit.ly/4rH8ygm
December 12, 2025 at 5:14 PM
Mark your calendars for April 10, 2026! 🗓️
Join us for the annual OHSU Knight Cancer Symposium in Portland, Oregon.
Stay updated on the latest advancements in cancer care, research, and programs.
Don't miss this opportunity to learn from experts!
Register today: https://bit.ly/4rH8ygm
Join us for the annual OHSU Knight Cancer Symposium in Portland, Oregon.
Stay updated on the latest advancements in cancer care, research, and programs.
Don't miss this opportunity to learn from experts!
Register today: https://bit.ly/4rH8ygm
New CAR-T therapy data 📊
Five-year data from a clinical trial for adults with relapsed or refractory large B-cell lymphoma confirms lasting remissions in high-risk patients, even years after treatment.
#OHSUResearch: https://bit.ly/4oL3BjJ
Five-year data from a clinical trial for adults with relapsed or refractory large B-cell lymphoma confirms lasting remissions in high-risk patients, even years after treatment.
#OHSUResearch: https://bit.ly/4oL3BjJ
December 11, 2025 at 9:04 PM
New CAR-T therapy data 📊
Five-year data from a clinical trial for adults with relapsed or refractory large B-cell lymphoma confirms lasting remissions in high-risk patients, even years after treatment.
#OHSUResearch: https://bit.ly/4oL3BjJ
Five-year data from a clinical trial for adults with relapsed or refractory large B-cell lymphoma confirms lasting remissions in high-risk patients, even years after treatment.
#OHSUResearch: https://bit.ly/4oL3BjJ
“Health care in this country is facing obstacles like never before. The attack on biomedical research funding is unprecedented.”
- @coussenslab.bsky.social on the challenges and opportunities impacting our state’s cancer research ecosystem (via the Portland Business Journal): https://bit.ly/48yHK99
- @coussenslab.bsky.social on the challenges and opportunities impacting our state’s cancer research ecosystem (via the Portland Business Journal): https://bit.ly/48yHK99
December 10, 2025 at 5:47 PM
“Health care in this country is facing obstacles like never before. The attack on biomedical research funding is unprecedented.”
- @coussenslab.bsky.social on the challenges and opportunities impacting our state’s cancer research ecosystem (via the Portland Business Journal): https://bit.ly/48yHK99
- @coussenslab.bsky.social on the challenges and opportunities impacting our state’s cancer research ecosystem (via the Portland Business Journal): https://bit.ly/48yHK99
Drs. Lisa Coussens, Shivaani Kummar, and Shannon McWeeney discuss the challenges and opportunities impacting our state’s cancer research ecosystem and what is needed to maintain and accelerate the pace of innovation with the Portland Business Journal.
Learn more: https://bit.ly/48yHK99
Learn more: https://bit.ly/48yHK99
December 8, 2025 at 8:23 PM
Drs. Lisa Coussens, Shivaani Kummar, and Shannon McWeeney discuss the challenges and opportunities impacting our state’s cancer research ecosystem and what is needed to maintain and accelerate the pace of innovation with the Portland Business Journal.
Learn more: https://bit.ly/48yHK99
Learn more: https://bit.ly/48yHK99
Reposted by OHSU Knight Cancer Institute
Chris Eide discussing our new platform that predicts tumor responsiveness and patient outcome for standard-of-care therapies in AML #ASH25 @ohsuknight.bsky.social
December 7, 2025 at 10:14 PM
Chris Eide discussing our new platform that predicts tumor responsiveness and patient outcome for standard-of-care therapies in AML #ASH25 @ohsuknight.bsky.social
Mark your calendars for April 10, 2026! 🗓️
Join us for the annual OHSU Knight Cancer Symposium in Portland, Oregon.
Stay updated on the latest advancements in cancer care, research, and programs.
Don't miss this opportunity to learn from experts!
Register today: https://bit.ly/4rH8ygm
Join us for the annual OHSU Knight Cancer Symposium in Portland, Oregon.
Stay updated on the latest advancements in cancer care, research, and programs.
Don't miss this opportunity to learn from experts!
Register today: https://bit.ly/4rH8ygm
December 5, 2025 at 7:10 PM
Mark your calendars for April 10, 2026! 🗓️
Join us for the annual OHSU Knight Cancer Symposium in Portland, Oregon.
Stay updated on the latest advancements in cancer care, research, and programs.
Don't miss this opportunity to learn from experts!
Register today: https://bit.ly/4rH8ygm
Join us for the annual OHSU Knight Cancer Symposium in Portland, Oregon.
Stay updated on the latest advancements in cancer care, research, and programs.
Don't miss this opportunity to learn from experts!
Register today: https://bit.ly/4rH8ygm